Copenhagen - Delayed Quote ? DKK ChemoMetec A/S (CHEMM.CO) Follow Compare 409.80 -6.60 (-1.59%) At close: October 25 at 4:59 PM GMT+2 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Closing of acquisition of Ovizio Imaging Systems SA ANNOUNCEMENT NO. 281 22 October 2024 Closing of acquisition of Ovizio Imaging Systems SA All capital owners have now accepted ChemoMetec's takeover offer, and closing has been completed today and thus the final acquisition of 100% of the capital in the Belgian company Ovizio Imaging Systems SA for the previously announced purchase price of EUR 2,830,000. Additional information Martin Helbo Behrens, CEOTel.: (+45) 48 13 10 20 Kim Nicolajsen, CFOTel.: (+45) 48 13 10 20 About Ovizio Ovizio has deve GlobeNewswire ? 3 days ago CHEMM.CO -1.59% Acquisition of Ovizio Imaging Systems SA ANNOUNCEMENT NO. 280 16 October 2024 Acquisition of Ovizio Imaging Systems SA On the basis of the completed due diligence, ChemoMetec today submitted a binding tender offer for the acquisition of 100% of the shares of Belgian company Ovizio Imaging Systems SA (’Ovizio’). The acquisition price is EUR 2,830,000. The tender offer has already been accepted by shareholders owning more than two thirds of Ovizio, and ChemoMetec is currently in the process of obtaining acceptance from the remaining shar GlobeNewswire ? 9 days ago CHEMM.CO -1.59% Upgrade of revenue and operating profit guidance ANNOUNCEMENT NO. 279 16 October 2024 Upgrade of revenue and operating profit guidance ChemoMetec sustained its positive performance in the first quarter of 2024/25 with better-than-expected sales and order intake. Based on this, the Company now expects revenue for the 2024/25 financial year in the DKK 445-460 million range, up from DKK 435-450 million in the most recent guidance, and EBITDA in the DKK 222-230 million range, up from DKK 216-223 million previously. ChemoMetec’s interim report for GlobeNewswire ? 9 days ago CHEMM.CO -1.59% ChemoMetec’s potential acquisition of Ovizio Imaging Systems SA ANNOUNCEMENT NO. 278 11 October 2024 ChemoMetec’s potential acquisition of Ovizio Imaging Systems SA As mentioned in company announcement no. 276, ChemoMetec has made an indicative purchase offer for the Belgian company Ovizio Imaging Systems SA. As also stated in the announcement, ChemoMetec expected to complete the due diligence within three weeks and most likely to complete the acquisition, if the outcome was positive. The mentioned due diligence and negotiations on the final share purchase a GlobeNewswire ? 14 days ago CHEMM.CO -1.59% Procedure of the Annual General Meeting ANNOUNCEMENT NO. 277 10 October 2024 Procedure of the Annual General Meeting The Annual General Meeting of ChemoMetec A/S was held on 10 October 2024 at 5.30 p.m. at Nordsj?llands KonferenceCenter. At the Annual General Meeting, the Board of Directors' report on the company's activities during the past year was presented, the annual report for 2023/24 was approved, and the Board of Directors and the Executive Board were granted discharge. The Annual General Meeting approved the proposal of the B GlobeNewswire ? 15 days ago CHEMM.CO -1.59% ChemoMetec makes offer to buy Ovizio Imaging Systems SA ANNOUNCEMENT NO. 276 20 September 2024 ChemoMetec makes offer to buy Ovizio Imaging Systems SA ChemoMetec has submitted an indicative offer to buy Belgian company Ovizio Imaging Systems (‘Ovizio’), which has been accepted by the company’s group of owners. ChemoMetec now has three weeks to carry out a due diligence, and if the outcome of this is positive, ChemoMetec will most likely proceed with the acquisition. Ovizio has developed a cell counter based on holographic microscopy. The instrument i GlobeNewswire ? last month CHEMM.CO -1.59% Notification of managers’ transactions ANNOUNCEMENT NO. 274 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of CFO Kim Nicolajsen in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) 48 13 10 20 A GlobeNewswire ? last month CHEMM.CO -1.59% Annual Report 2023/24 - Strengthened commercial focus after challenging year ANNOUNCEMENT NO. 273 11 September 2024 Annual Report 2023/24 (1 July 2023 - 30 June 2024) Strengthened commercial focus after challenging year ChemoMetec’s revenue fell by 8% in 2023/24 to DKK 407.4 million, and operating profit (EBITDA) was down by 26% to DKK 186.2 million. Revenue was adversely affected by a 35% decline in sales of instruments, while sales of consumables and services were up by 13% in total. During the year, ChemoMetec initiated a gradual launch of the XcytoMatic 40 and XcytoM GlobeNewswire ? last month CHEMM.CO -1.59% Guidance for the 2024/25 financial year ANNOUNCEMENT NO. 272 11 September 2024 Guidance for the 2024/25 financial year ChemoMetec has today approved the annual report for 2023/24, including the guidance for 2024/25, which is considered inside information. For 2024/25, ChemoMetec expects revenue in the range of DKK 435-450 million (2023/24: DKK 407.4 million) and EBITDA in the range of DKK 216-223 (2023/24: DKK 186.2 million). The annual report for 2023/24, which is released along with this announcement, sets out the underlying assumpt GlobeNewswire ? last month CHEMM.CO -1.59% Major shareholder announcement – BlackRock, Inc. 4 July 2024 Major shareholder announcement – BlackRock, Inc. ANNOUNCEMENT NO. 271 Major shareholder announcement – BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec A/S that BlackRock Investment Management (UK) Limited on 3 July 2024, increased its holding of voting rights attached to shares and voting rights in ChemoMetec A/S to above 10%, and that the holding thus exceeds the 10 per cent limit in section 38 of GlobeNewswire ? 3 months ago CHEMM.CO -1.59% Preliminary revenue figures for the 2023/24 financial year ANNOUNCEMENT NO. 270 2 July 2024 Preliminary revenue figures for the 2023/24 financial year In the fourth quarter of the 2023/24 financial year, ChemoMetec's revenue was DKK 109.2 million, corresponding to a growth of 13.5% from the year-earlier period. The revenue for the 2023/24 financial year was DKK 407.4 million against DKK 442.3 million the previous year, corresponding to a decrease of 7.9%. The revenue in 2023/24 is thus in line with the latest disclosed guidance for the revenue of DKK 40 GlobeNewswire ? 3 months ago CHEMM.CO -1.59% Appointment of new CFO ANNOUNCEMENT NO. 269 Appointment of new CFO The board of ChemoMetec has appointed Kim Nicolajsen as new CFO with effect from 1 July 2024. Kim Nicolajsen comes from a similar position as CFO in the family-owned company Rohde Nielsen. He is state-authorized public accountant and has previously worked for KPMG and EY. The board has also entered into an agreement with the company's current CFO Niels H?y Nielsen that he will resign from his position at the same time as Kim Nicolajsen takes over. The GlobeNewswire ? 4 months ago CHEMM.CO -1.59% Q3 2023/24 - First sale of the XM30 completed ANNOUNCEMENT NO. 262 Trading statement for Q3 2023/24 (1 January - 31 March 2024) First sale of the XM30 completed Revenue declined by 6% in the third quarter of 2023/24 to DKK 98.9 million from DKK 105.4 million in the year-earlier period. The development reflected continued growth in sales of consumables and services, set off by declining sales of instruments as customers continued to show restraint in purchasing new instruments. EBITDA fell to DKK 43.1 million in the third quarter, being affe GlobeNewswire ? 5 months ago CHEMM.CO -1.59% Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year ANNOUNCEMENT NO. 261 Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year According to the preliminary figures, revenue in the third quarter of 2023/24 was DKK 98.9 million and in the first nine months of 2023/24 DKK 298.2 million. Based on the development in the third quarter of 2023/24 and the expectations for the remaining part of the financial year, expectations for revenue for the 2023/24 financial year are clarified. Hence, revenue in GlobeNewswire ? 6 months ago CHEMM.CO -1.59% Major shareholder announcement – Swedbank Robur Fonder AB ANNOUNCEMENT NO. 259 Major shareholder announcement Major shareholder announcement – Swedbank Robur Fonder AB Pursuant to Section 38 of the Danish Capital Markets Act, it is hereby announced that Swedbank Robur Fonder AB has informed ChemoMetec A/S that Swedbank Robur Fonder AB on 2 April 2024, decreased its holding of shares and voting rights to below 5% of the total share capital and voting rights in ChemoMetec A/S. Additional information Niels H?y Nielsen, CFOTelephone (+45) 2551 8724 About C GlobeNewswire ? 6 months ago CHEMM.CO -1.59% Major shareholder announcement – AIM International Mutual Funds ANNOUNCEMENT NO. 257 Major shareholder announcement Major shareholder announcement – AIM International Mutual Funds Pursuant to Section 30 of the Danish Capital Markets Act, it is hereby announced that Invesco Ltd. has informed ChemoMetec A/S that AIM International Mutual Funds (Invesco International Mutual Funds) on 13 March 2024, increased its holding of shares and voting rights to above 5% of the total share capital and voting rights in ChemoMetec A/S, and that the holding thus exceeds the 5 GlobeNewswire ? 7 months ago CHEMM.CO -1.59% Major shareholder announcement – Invesco Ltd. ANNOUNCEMENT NO. 256 Major shareholder announcement Major shareholder announcement – Invesco Ltd. Pursuant to Section 30 of the Danish Capital Markets Act, it is hereby announced that Invesco Ltd. has informed ChemoMetec A/S that Invesco Ltd. on 13 March 2024, increased its holding of voting rights to above 5% of the total voting rights in ChemoMetec A/S, and that the holding thus exceeds the 5 per cent limit in section 38 of the Capital Markets Act. Additional information Niels H?y Nielsen, CFO GlobeNewswire ? 7 months ago CHEMM.CO -1.59% Appointment of new CEO ANNOUNCEMENT NO. 255 (Changed category - Inside information) Appointment of new CEO The Board of Directors of ChemoMetec has decided to appoint the company's current COO Martin Helbo Behrens as new CEO, effective as of today. The decision is based on the Board’s assessment that ChemoMetec in the current phase of the company's development needs a different composition of executive management skills. Therefore, the board has entered into an agreement with the company's current CEO Rasmus Kofoed to GlobeNewswire ? 7 months ago CHEMM.CO -1.59% Interim report for the first half of 2023/24 – Correction ANNOUNCEMENT NO. 250 5 February 2024 Interim report for the first half of 2023/24 – Correction In connection with the previously published interim report for the first half of 2023/24 (announcement no. 249), there were errors in the sales and operating results highlights: EBITDA for the second quarter fell by 36% to DKK 93.1 million, and the EBITDA margin was 48%, compared with 63% in the year-earlier period. EBITDA for the first half fell by 36% to DKK 145.2 million, and the EBITDA margin was 4 GlobeNewswire ? 8 months ago CHEMM.CO -1.59% Interim report 2023/24 - Full-year guidance maintained despite continued challenging market conditions ANNOUNCEMENT NO. 249 5 February 2024 Interim report for the first half of 2023/24 Full-year guidance maintained despite continued challenging market conditions Rasmus Kofoed, CEO: “Rasmus Kofoed, CEO: “In the second quarter, we saw early signs of market conditions improving within our key market area, cell-based therapy, but the investment climate remains subdued. Our revenue therefore continued to be under pressure, as expected, declining 15% year-on-year to DKK 108.1 million. Lower sales of in GlobeNewswire ? 8 months ago CHEMM.CO -1.59% Performance Overview Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index Return CHEMM.CO OMX Copenhagen 25 Index YTD +6.80% +5.36% 1-Year +49.81% +19.08% 3-Year -55.37% -2.42%
